Search Videos and More
Video
Matthew Davids, MD, MMSc discusses time-limited AVO triplet therapy
In a new study published in the Journal of Clinical Oncology and presented at #ASH24, Matthew Davids, MD, MMSC, of Dana-Farber Cancer Institute, shared promising findings: a time-limited AVO triplet therapy offers durable remission for high-risk CLL patients.
Video
Jennifer Brown, MD, PhD reviews Phase 2 Amplify trial
Dana-Farber Cancer Institute's Jennifer Brown, MD, PhD, shared results at #ASH24 from the Phase 3 AMPLIFY trial: novel oral regimens show promise for CLL with durable, deep responses.
Video
Ann Lacasce, MD, MMSc discusses treatment in early stage high-risk cHL patients
Ann Lacasce MD, MMSc, of Dana-Farber Cancer Institute presented findings at #ASH24 suggesting treatment with brentuximab vedotin and nivolumab can reduce toxicities and may decrease the need for radiation in early stage high-risk cHL patients.
Video
Daniel DeAngelo, MD, PhD on a novel systemic mastocytosis (SM) drug
Daniel DeAngelo, MD, PhD, of Dana-Farber Cancer Institute, presented findings at #ASH24 on two abstracts regarding a novel systemic mastocytosis (SM) drug with high response rates & a tool that identifies SM subtypes with 90% accuracy.
News
Study Finds Care After Donor Stem Cell Transplant Can Be Safely Shared Between Transplant Centers and Local Oncologists
Patients undergoing a donor stem-cell transplant for leukemia or other blood-related cancer require months of specialized follow-up care, traditionally delivered at the center where they received their transplant – often a serious challenge for those who live far away.
News
New Research Shows Inherited Genetic Variants Increase Risk of Certain Pediatric Cancers
New research from Dana-Farber Cancer Institute has found that rare germline genetic abnormalities could increase the risk of childhood cancers such as neuroblastoma, Ewing sarcoma, and osteosarcoma.
News
Dana-Farber Research News 01.01.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from December 1 through December 15.
News
Turning Up the Heat: Dana-Farber Scientists Describe Key Molecular Shift in Brown Fat Cells
Brown fat is a specialized tissue that has developed a host of important functions over the course of evolution. One of the most critical: the ability to produce heat in response to low temperatures by burning energy.
Video
Ann Partridge, MD, MPH Presents PROs from the COMET Study
Patients with low-risk DCIS who underwent active monitoring had comparable physical, emotional, and psychological outcomes to patients who received standard treatment, according to results from the phase 3 COMET trial data.
Video
Judy Garber, MD, MPH Presents Updated Results of the OlympiA Study
Dana-Farber’s Judy Garber, MD, MPH shared updated results from the phase 3 OlympiA study. The new analysis provides further support for olaparib’s benefits in patients with high-risk, HER2-negative breast cancer with germline mutations in BRCA1 or BRCA2.
Video
Ada Waks, MD Presents Results of the MARGOT Study
Dana-Farber's Ada Waks, MD presented results of MARGOT, a phase 2 trial comparing margetuximab plus chemo or trastuzumab plus chemo in patients with early stage HER2+ breast cancer.
Video
Antonio Giordano, MD, PhD Discusses Novel CDK4-Selective Inhibitor
Dana-Farber's Antonia Giordano, MD, PhD shares new data on a novel CDK4-selective inhibitor in como with letrozole as 1st line treatment in HR+/HER2 Metastatic Breast Cancer.